BerGenBio Presents Preliminary Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC in Elderly AML Patients at ASH 2019

Corporate Breaking News

Home : BerGenBio Presents Preliminary Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC in Elderly AML Patients at ASH 2019

Dec 09 2019	BerGenBio Presents Preliminary Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC in Elderly AML Patients at ASH 2019
BERGEN, Norway, Dec. 9, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, will today provide an update from the Company's phase II study of bemcentinib (BGB324), a...


Source:https://www.prnewswire.com:443/news-releases/bergenbio-presents-preliminary-clinical-data-from-phase-ii-combination-trial-of-bemcentinib-and-ldac-in-elderly-aml-patients-at-ash-2019-300971109.html

Related News
» Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag) for the treatment of Chronic Immune Thrombocytopenia Provides Evidence of Long-term Response Rates » Doptelet ® (avatrombopag) Demonstrates Cost-effectiveness for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease